Patents Assigned to Mor Research Applications, Ltd.
  • Publication number: 20080138331
    Abstract: A method is described for the diagnosis of an ovarian or endometrial tumor or for a prognosis, characterized in that the L1 level is determined in a patient sample, preferably via an anti L1 antibody, the presence of L1 being an indication of the presence of an ovarian or endometrial tumor or a predisposition for such a tumor. Furthermore, methods for treating of ovarian or endometrial tumors are provided.
    Type: Application
    Filed: October 2, 2007
    Publication date: June 12, 2008
    Applicants: Mor Research Applications, Ltd., Deutsches Krebsforschungszentrum Stiftung des Offentlichen Rechts
    Inventors: Peter Altevogt, Mina Fogel
  • Publication number: 20080051440
    Abstract: Methods and compositions for regulating food intake in a human subject; for improving a compliance of a human subject to caloric restriction; and for reducing a desire of a human subject to consume fats, utilizing H1-receptor agonists that have a pharmacological half-life that allows am efficient treatment regime thereof are disclosed. The methods and compositions can be efficiently used for treating conditions such as overeating, overweight, obesity, binge eating disorder, night eating syndrome, obsessive eating, compulsive eating and bulimia, as well as conditions associated with metabolic derangement such as dyslipidemia and for preventing or reducing weight gain due to factors such as drug use, cessation of smoking, and the like in a human subject.
    Type: Application
    Filed: August 3, 2007
    Publication date: February 28, 2008
    Applicant: Mor Research Applications Ltd.
    Inventor: Nir Barak
  • Publication number: 20080051439
    Abstract: Methods for regulating food intake in a human subject; for improving a compliance of a human subject to caloric restriction; and for reducing a desire of a human subject to consume fats, utilizing H1-receptor agonists that have a pharmacological half-life that allows an efficient treatment regime thereof are disclosed. The methods can be efficiently used for treating conditions such as overeating, overweight, obesity, binge eating disorder, night eating syndrome, obsessive eating, compulsive eating and bulimia, as well as conditions associated with metabolic derangement such as dyslipidemia.
    Type: Application
    Filed: August 3, 2007
    Publication date: February 28, 2008
    Applicant: Mor Research Applications Ltd.
    Inventor: Nir Barak
  • Patent number: 7332582
    Abstract: The present invention provides to a humanized monoclonal antibody having immunostimulatory effects. This antibody binds specifically to B lymphoblastoid cells, induces proliferation and activation of peripheral blood lymphocytes, and is capable of eliciting an anti-tumor effect upon administration to subjects suffering from cancer.
    Type: Grant
    Filed: November 19, 2004
    Date of Patent: February 19, 2008
    Assignees: CureTech Ltd., Mor-Research Applications Ltd.
    Inventors: Britta Hardy, Steven Tarran Jones, Leah Klapper
  • Patent number: 7329639
    Abstract: The present invention provides peptides and polynucleotides, and their use for immunomodulation, immunotherapy and vaccine particularly for anti-cancer therapy, and for diagnosis purposes. The immunomodulatory effect includes induction of proliferation and activation of peripheral blood lymphocytes and induction of an anti-tumor effect upon administration of peptides of the invention to subjects suffering from cancer.
    Type: Grant
    Filed: April 27, 2006
    Date of Patent: February 12, 2008
    Assignees: CureTech Ltd., Mor-Research Applications Ltd.
    Inventors: Britta Hardy, Annat Raiter, Leah Klapper
  • Publication number: 20080025980
    Abstract: The present invention provides to a humanized monoclonal antibody having immunostimulatory effects. This antibody binds specifically to B lymphoblastoid cells, induces proliferation and activation of peripheral blood lymphocytes, particularly T cells, and is capable of eliciting an anti-tumor effect upon administration to subjects suffering from cancer.
    Type: Application
    Filed: September 12, 2007
    Publication date: January 31, 2008
    Applicants: CureTech Ltd., Mor-Research Applications Ltd.
    Inventors: Britta Hardy, Steven Jones, Leah Klapper
  • Publication number: 20080004324
    Abstract: Methods for preventing or reducing weight gain due to factors such as drug use, cessation of smoking, and the like in a human subject, utilizing H1-receptor agonists that have a pharmacological half-life that allows an efficient treatment regime thereof are disclosed.
    Type: Application
    Filed: August 3, 2007
    Publication date: January 3, 2008
    Applicant: Mor Research Applications Ltd.
    Inventor: Nir Barak
  • Publication number: 20080004254
    Abstract: Methods and compositions for regulating food intake in a human subject; for improving a compliance of a human subject to caloric restriction; and for reducing a desire of a human subject to consume fats, utilizing H1-receptor agonists that have a pharmacological half-life that allows an efficient treatment regime thereof are disclosed. The methods and compositions can be efficiently used for treating conditions such as overeating, overweight, obesity, binge eating disorder, night eating syndrome, obsessive eating, compulsive eating and bulimia, as well as conditions associated with metabolic derangement such as dyslipidemia and for preventing or reducing weight gain due to factors such as drug use, cessation of smoking, and the like in a human subject.
    Type: Application
    Filed: August 3, 2007
    Publication date: January 3, 2008
    Applicant: Mor Research Applications Ltd.
    Inventor: Nir Barak
  • Publication number: 20080003306
    Abstract: Methods and compositions for regulating food intake in a human subject; for improving a compliance of a human subject to caloric restriction; and for reducing a desire of a human subject to consume fats, utilizing H1-receptor agonists that have a pharmacological half-life that allows an efficient treatment regime thereof are disclosed. The methods and compositions can be efficiently used for treating conditions such as overeating, overweight, obesity, binge eating disorder, night eating syndrome, obsessive eating, compulsive eating and bulimia, as well as conditions associated with metabolic derangement such as dyslipidemia and for preventing or reducing weight gain due to factors such as drug use, cessation of smoking, and the like in a human subject.
    Type: Application
    Filed: August 3, 2007
    Publication date: January 3, 2008
    Applicant: Mor Research Applications Ltd.
    Inventor: Nir Barak
  • Publication number: 20080004322
    Abstract: Methods for regulating food intake in a human subject; for improving a compliance of a human subject to caloric restriction; and for reducing a desire of a human subject to consume fats, utilizing H1-receptor agonists that have a pharmacological half-life that allows an efficient treatment regime thereof are disclosed. The methods can be efficiently used for treating conditions such as overeating, overweight, obesity, binge eating disorder, night eating syndrome, obsessive eating, compulsive eating and bulimia, as well as conditions associated with metabolic derangement such as dyslipidemia.
    Type: Application
    Filed: August 3, 2007
    Publication date: January 3, 2008
    Applicant: Mor Research Applications Ltd.
    Inventor: Nir Barak
  • Publication number: 20060276390
    Abstract: Compositions and methods for the treatment of graft rejection associated with transplantation of tissues and organs include combined treatment involving at least one agent selected from Copolymer 1, a copolymer 1-related heteropolymer or an ordered peptide in combination with at least one additional known immunosuppressive agent. Compositions and methods for the treatment of graft rejection using ordered peptides or ordered copolymer 1-related heteropolymers as monotherapy are also provided.
    Type: Application
    Filed: August 4, 2006
    Publication date: December 7, 2006
    Applicants: YEDA RESEARCH AND DEVELOPMENT CO. LTD., MOR RESEARCH APPLICATIONS LTD.
    Inventors: Rina Aharoni, Ruth Arnon, Michael Sela, Alex Yussim
  • Patent number: 7122372
    Abstract: The present invention provides peptides and polynucleotides, and their use for immunomodulation, immunotherapy and vaccine particularly for anti-cancer therapy, and for diagnosis purposes. The immunomodulatory effect includes induction of proliferation and activation of peripheral blood lymphocytes and induction of an anti-tumor effect upon administration of peptides of the invention to subjects suffering from cancer.
    Type: Grant
    Filed: April 9, 2004
    Date of Patent: October 17, 2006
    Assignees: CureTech Ltd., Mor-Research Applications Ltd.
    Inventors: Britta Hardy, Annat Raiter, Leah Klapper
  • Publication number: 20060210573
    Abstract: The present invention provides peptides and polynucleotides, and their use for immunomodulation, immunotherapy and vaccine particularly for anti-cancer therapy, and for diagnosis purposes. The immunomodulatory effect includes induction of proliferation and activation of peripheral blood lymphocytes and induction of an anti-tumor effect upon administration of peptides of the invention to subjects suffering from cancer.
    Type: Application
    Filed: April 27, 2006
    Publication date: September 21, 2006
    Applicants: Curetech Ltd.,, Mor-Research Applications Ltd.,
    Inventors: Britta Hardy, Annat Raiter, Leah Klapper
  • Publication number: 20060166204
    Abstract: Specific PON1 and ACHE alleles segregate in linkage, forming an haplotype which directly correlates with higher susceptibility to develop Parkinson's Disease (PD). This PD-susceptibility haplotype is herein presented as a tool for predicting the risk of developing Parkinson's Disease and its severity, both for an individual and for the population in general. Thus, the present invention provides the use of said PD-susceptibility haplotype in diagnostic and screening methods.
    Type: Application
    Filed: September 24, 2003
    Publication date: July 27, 2006
    Applicants: Yissum Research Development Company of the Hebrew University of Jerusalem, Mor Research Applications Ltd., Ben-Gurion University of Negev, Research & Development Authority
    Inventors: Hermona Soreq, Liat Ben-Moyal, Boris Bryk, Alon Friedman
  • Publication number: 20060099209
    Abstract: The invention concerns novel DNA and amino acid sequences of monoclonal antibodies. (mAbs) raised against lymphoblastoid cells and peptides to which the mAbs bind to. The invention also concerns diagnostic assays using said antibodies or peptides for detecting individuals with a high probability of having a malignant disease and, at times, for detecting an individual having a specific malignant disease. The invention further concerns pharmaceutical compositions comprising the mAbs or peptides of the invention for use in the treatment of various malignant diseases as well as methods for the treatment of malignant diseases using the mAbs or peptides of the invention.
    Type: Application
    Filed: December 23, 2005
    Publication date: May 11, 2006
    Applicant: MOR RESEARCH APPLICATIONS LTD.
    Inventors: Britta Hardy, Abraham Novogrodsky
  • Publication number: 20050017179
    Abstract: The invention presents methods of using Fourier transform infrared microspectroscopy (FTIR-MSP) for distinguishing between normal and abnormal human cells and for diagnosis and digital staging of human cells on biopsied samples. The invention further presents computational methods employing neural network (NN) based classifiers for diagnosis and digital staging of adenomatous polyp and malignant tissue types of biopsied samples of human cells.
    Type: Application
    Filed: May 14, 2004
    Publication date: January 27, 2005
    Applicants: BEN-GURION UNIVERSITY OF THE NEGEV, MOR RESEARCH APPLICATIONS LTD.
    Inventors: Shaul Mordechai, Jed Goldstein, Shmuel Argov, Hugo Guterman, Jagannathan Ramesh
  • Publication number: 20040197832
    Abstract: A method is provided for determining the gender and/or chromosomal abnormality, e.g. chromosomal aneuploidy of a fetus comprising identifying fetal cells in a transcervical cell sample obtained from a pregnant woman, for example with an antibody specific to the HLA-G antigen expressed only by extravillous trophoblast cells, and then subjecting the identified fetal cells to fluorescence in situ hybridization (FISH) with one or more probes for detecting the sex of the fetus or a chromosomal abnormality such as a monosomy, a trisomy or a polyploidy, e.g. triploidy.
    Type: Application
    Filed: April 3, 2003
    Publication date: October 7, 2004
    Applicant: Mor Research Applications Ltd.
    Inventors: Aliza Amiel, Moshe D. Fejgin
  • Publication number: 20030216316
    Abstract: Pharmaceutical compositions comprising erythropoietin are provided for treatment of cancer, particularly for treatment of multiple myeloma. Erythropoietin was found to be effective for inhibition of tumor growth, triggering of tumor regression, stimulation of the natural immunological defense against cancer and/or inhibition of cancer cell metastasis.
    Type: Application
    Filed: March 5, 2003
    Publication date: November 20, 2003
    Applicants: Yeda Research and Development Co. Ltd., MOR Research Applications Ltd.
    Inventors: Nechama Haran-Ghera, Moshe Mittelman, Alpha Peled
  • Patent number: 6579525
    Abstract: Pharmaceutical compositions comprising erythropoietin are provided for treatment of cancer, particularly for treatment of multiple myeloma. Erythropoietin was found to be effective for inhibition of tumor growth, triggering of tumor regression, stimulation of the natural immunological defense against cancer and/or inhibition of cancer cell metastasis.
    Type: Grant
    Filed: October 5, 2000
    Date of Patent: June 17, 2003
    Assignees: Yeda Research and Development Co. Ltd., Mor Research Applications Ltd.
    Inventors: Nechama Haran-Ghera, Moshe Mittelman, Alpha Peled
  • Patent number: 6503246
    Abstract: An intralesional method for treating a hypertrophic scar or keloid using a cryoprobe. The method comprises: (a) inserting the cryoprobe into the hypertrophic scar or keloid so that the cryoprobe is positioned within the hypertrophic scar or keloid; and (b) introducing a cryogen into the cryoprobe thereby freezing the hypertrophic scar or keloid. The cryoprobe has a sealed distal end comprising a cutting tip. Also disclosed is a cryoprobe comprising an elongated, uninsulated housing having a sealed distal end and a proximal end. The housing comprises therein a cryogen inlet tube. The cryoprobe further comprises a cutting tip at the distal end of the housing and a cryogen vent adjacent to the proximal end and in fluid communication with the interior of the housing.
    Type: Grant
    Filed: July 5, 2000
    Date of Patent: January 7, 2003
    Assignees: Mor Research Applications Ltd., Cleanetica Ltd.
    Inventors: Yaron Har-Shai, Micha Amar